cyclophilin
cypa
member
cyclophilin
famili
highli
homolog
peptidyl
prolyl
cistran
isomeras
ppias
bind
cyclosporin
csa
cypa
play
critic
role
variou
biolog
process
includ
protein
fold
assembl
transport
regul
neuron
growth
hiv
replic
discoveri
cypa
inhibitor
great
special
interest
treatment
immunolog
disord
studi
seri
novel
small
molecular
cypa
inhibitor
discov
use
structurebas
virtual
screen
conjunct
chemic
synthesi
bioassay
databas
contain
small
molecular
compound
search
virtual
screen
crystal
structur
human
cypa
sprbase
bind
affin
assay
compound
found
show
bind
affin
cypa
submicromolar
micromolar
level
compound
seven
compound
select
start
point
structur
modif
consid
bind
activ
synthesi
difficulti
structur
similar
thu
synthes
new
small
molecular
compound
four
compound
show
high
cypa
ppias
inhibit
activ
ic
lm
pharmacolog
assay
indic
four
compound
demonstr
somewhat
inhibit
activ
prolifer
spleen
cell
cyclophilin
discov
origin
high
affin
cyclosporin
csa
immunosuppress
drug
use
prevent
allograft
reject
gener
biolog
function
cyclophilin
catalyz
cistran
isomer
peptid
bond
preced
prolin
protein
peptid
known
human
cyclophilin
cyclophilin
hcypa
one
import
member
wide
studi
map
biolog
function
addit
bind
target
csa
hcypa
abl
enhanc
rate
fold
unfold
protein
via
peptidylprolyl
isomeras
ppias
activ
hcypa
perform
essenti
function
replic
bind
specif
capsid
domain
ca
gag
polyprotein
hcypa
may
also
render
neuroprotect
neurotroph
effect
present
high
level
brain
recent
discov
nucleocapsid
n
protein
sar
coronaviru
sarscov
bind
hcypa
may
associ
sarscov
infect
cypa
attract
consider
attent
novel
catalyt
activ
also
therapeut
signific
report
cypacsa
bind
might
inhibit
serinethreonin
phosphatas
activ
calcineurin
therebi
block
product
cytokin
includ
interferon
c
discoveri
csa
two
decad
ago
herald
new
era
field
organ
transplant
sinc
number
transplant
organ
grown
continu
search
novel
immunosuppress
intensifi
howev
inhibitor
cypa
mainli
deriv
natur
sourc
rapamycin
sanglifehrin
peptid
analogu
larg
molecul
littl
report
regard
small
molecul
cypa
inhibitor
although
immunosuppress
like
csa
improv
rate
transplant
success
prolong
patient
surviv
side
effect
agent
sequenti
found
nephrotox
hypertens
cardiotox
therebi
prompt
us
discov
novel
small
molecul
cypa
inhibitor
order
decreas
side
effect
structurebas
ligand
design
led
identif
compound
current
clinic
trial
market
wealth
structur
function
inform
cypa
offer
solid
start
point
ration
structurebas
design
inhibitor
use
dockingbas
virtual
screen
approach
conjunct
surfac
plasmon
reson
spr
determin
novel
small
molecul
cypa
binder
hit
compound
discov
accord
bind
potenc
structur
similar
synthet
complex
seven
hit
compound
select
start
point
structur
optim
total
new
compound
includ
prepar
method
seven
compound
report
analogu
synthes
test
biolog
assay
final
four
compound
found
show
high
cypa
ppias
peptidylprolyl
isomeras
inhibit
activ
one
compound
activ
inhibit
prolifer
spleen
cell
spec
databas
contain
structur
inform
small
molecul
http
wwwspecsnet
spec
compani
suppli
compound
sampl
collect
differ
sourc
first
spec
databas
evalu
use
filter
druglik
nondruglik
molecul
remov
databas
final
potenti
druglik
molecul
select
dock
screen
molecul
save
databas
crystal
structur
cypa
complex
sanglifehrin
macrolid
sfm
pdb
entri
recov
brookhaven
protein
data
bank
http
wwwrcsborgpdb
use
target
virtual
screen
databas
http
wwwspecsnet
present
studi
program
employ
primari
screen
residu
cypa
around
sfm
radiu
isol
construct
grid
dock
screen
result
substructur
includ
residu
bind
pocket
dock
calcul
kollmanallatom
charg
assign
protein
gasteigermarsili
partial
charg
assign
small
molecul
databas
conform
flexibl
compound
databas
consid
dock
search
dock
suit
program
design
find
possibl
orient
ligand
site
orient
ligand
evalu
shape
score
function
andor
function
approxim
ligandreceptor
bind
energi
shape
score
function
empir
function
resembl
van
der
waal
attract
energi
ligandreceptor
bind
energi
taken
approxim
sum
van
der
waal
electrostat
interact
energi
initi
orient
score
evalu
gridbas
rigid
bodi
minim
carri
ligand
locat
nearest
local
energi
minimum
within
receptor
bind
site
posit
conform
dock
molecul
optim
use
singl
anchor
search
torsion
minim
method
thirti
configur
per
ligand
build
cycl
maximum
anchor
orient
use
anchorfirst
dock
algorithm
dock
configur
energi
minim
use
maximum
iter
minim
cycl
molecul
highest
score
obtain
dock
search
rescor
use
consensu
score
cscore
method
encod
bind
free
energi
bind
mode
top
molecul
cscore
cypa
calcul
model
use
flexx
program
encod
flexx
flexibl
dock
method
use
increment
construct
algorithm
place
ligand
activ
site
divid
ligand
small
fragment
build
increment
conform
flexibl
ligand
consid
reason
time
kollmanallatom
charg
gasteigermarsili
partial
charg
use
cyclophilin
candid
molecul
respect
flexx
simul
final
compound
distinguish
select
bioassay
basi
score
virtual
screen
druglik
analysi
virtual
screen
perform
sgi
origin
supercomput
design
analogu
compound
fig
bear
highest
bind
affin
cypa
obtain
surfac
plasmon
reson
spr
determin
see
section
candid
compound
select
virtual
screen
use
lead
compound
design
new
cypa
inhibitor
base
structur
enzym
bind
activ
featur
compound
new
analogu
tabl
design
synthes
first
round
keep
key
group
compound
quinolin
ring
sulfanilamid
moietyw
use
variou
setric
electron
hydrophob
group
substitut
posit
quinolin
ring
compound
fig
obtain
analogu
tabl
replac
quinolin
ring
pyridin
ring
obtain
seven
compound
tabl
keep
key
group
compound
alkyl
acylamid
sulfanilamid
moietyw
chang
length
alkyl
linker
coupl
sulfisoxazol
compound
obtain
four
compound
tabl
basi
structur
featur
compound
design
compound
tabl
maintain
dibenzo
acid
dibenzo
acid
ester
moieti
replac
group
compound
electron
hydrophob
substitut
benzamido
group
substitut
methylen
group
compound
ethylen
group
obtain
compound
tabl
synthet
procedur
scheme
depict
sequenc
reaction
led
prepar
compound
use
isatin
start
materi
gener
substitut
acid
prepar
isatin
condens
keton
ethanol
compound
convert
correspond
acyl
chlorid
reflux
socl
substitut
use
differ
sulfanilamid
give
target
compound
tabl
key
intermedi
requir
synthes
compound
prepar
compound
sulfam
deprotect
compound
synthes
rout
outlin
scheme
react
reflux
ammonium
format
hcooh
afford
compound
synthes
use
usui
method
compound
react
maleic
acid
min
target
compound
obtain
step
cd
scheme
employ
tabl
compound
synthes
use
process
compound
except
compound
replac
compound
synthet
rout
outlin
scheme
scheme
depict
sequenc
reaction
led
prepar
compound
use
anthranil
acid
start
materi
compound
synthes
heat
anthranil
acid
hcho
hcl
reflux
satur
hcl
methanol
afford
compound
acyl
variou
substitut
benzoyl
chlorid
pyridin
afford
compound
compound
react
benzyl
bromid
reflux
nmp
produc
compound
hydrolyz
use
lioh
afford
monoest
dicarboxyl
acid
respect
compound
synthes
rout
outlin
scheme
reflux
acid
satur
hcl
methanol
afford
compound
bromin
nb
chloroform
afford
compound
compound
coupl
compound
give
key
intermedi
presenc
nbuli
reduc
pdc
compound
obtain
nacyl
chlorid
pyridin
compound
obtain
condit
compound
compound
quantit
obtain
hydrolysi
use
lioh
room
temperatur
bind
assay
cypa
express
purifi
accord
previous
report
procedur
bind
affin
virtual
screen
candid
cypa
vitro
determin
employ
surfac
plasmon
reson
spr
technolog
measur
perform
use
dual
flow
cell
biacor
instrument
biacor
ab
uppsala
sweden
immobil
cypa
hydrophil
carboxymethyl
dextran
matrix
sensor
chip
biacor
carri
standard
primari
amin
coupl
reaction
wizard
cypa
coval
bound
matrix
dilut
mm
sodium
acet
buffer
ph
final
concentr
mgml
equilibr
baselin
complet
continu
flow
hbsep
run
buffer
mm
hepe
mm
nacl
mm
edta
vv
surfact
ph
chip
h
biacor
data
collect
hbsep
run
buffer
constant
flow
rate
llmin
sensorgram
process
use
automat
correct
nonspecif
bulk
refract
index
effect
equilibrium
constant
k
valu
evalu
proteinligand
bind
affin
determin
steadi
state
affin
fit
analysi
biacor
data
enzymat
activ
assay
cypa
ppias
activ
measur
use
standard
chymotrypsincoupl
assay
assay
buffer
mm
hepe
mm
nacl
ph
cypa
nm
stock
solut
precool
ad
mgml
chymotrypsin
mm
hcl
reaction
initi
ad
mm
peptid
substrat
sucalaalacisprophepna
liclthf
solut
rapid
invers
delay
onset
mix
usual
absorb
pnitroanilin
follow
nm
reaction
complet
min
final
concentr
licl
assay
mm
thf
present
concentr
vv
absorb
read
collect
everi
spectrophotomet
progress
curv
analyz
nonlinear
leastsquar
fit
inhibit
assay
compound
perform
manner
mention
aliquot
compound
dmso
ad
cypa
solut
assay
buffer
preincub
h
assay
start
addit
chymotrypsin
substrat
calcul
halfmaxim
inhibitori
concentr
ic
percent
remain
ppias
activ
plot
common
logarithm
compound
concentr
data
fit
use
sigmoid
fit
model
softwar
femal
icr
strain
mice
week
old
g
purchas
experiment
anim
hous
china
pharmaceut
univers
nanj
china
maintain
plastic
cage
free
access
pellet
food
water
h
lightdark
cycl
studi
compli
current
ethic
regul
anim
research
nanj
univers
mice
use
treat
human
spleen
asept
taken
mice
crush
gentli
separ
singl
cell
squeez
ml
solut
gibcobrl
cell
obtain
pass
eight
layer
gauz
centrifug
revmin
min
pellet
ad
ml
steril
tri
hydroxymethyl
aminomethan
contain
nh
cl
ph
follow
centrifug
remov
erythrocyt
wash
twice
rpmi
contain
u
ml
penicillin
u
ml
streptomycin
fetal
calf
serum
fc
rpmi
medium
resuspend
rpmi
medium
use
cell
cultur
spleen
cell
cultur
flatbottom
micropl
falcon
densiti
cell
per
well
rpmi
medium
ml
stimul
lg
ml
con
h
co
air
presenc
absenc
control
group
variou
concentr
compound
cell
growth
evalu
modifi
mtt
assay
briefli
mg
ml
mtt
rpmi
ad
h
incub
remov
supernat
dmso
ad
dissolv
formazan
crystal
plate
shaken
min
read
elisa
reader
sunris
remotetouch
screen
tecan
austria
nm
assay
run
triplic
effect
compound
prolifer
mous
spleen
cell
induc
con
calcul
eq
inhibitori
rate
compound
data
express
mean
sd
signific
differ
group
statist
analysi
evalu
oneway
analysi
varianc
follow
twotail
test
evalu
differ
enc
two
group
test
control
group
multipl
dose
group
oneway
analysi
varianc
reveal
signific
effect
p
target
crystal
structur
cypa
pdb
entri
search
databas
use
small
molecul
rank
accord
score
calcul
use
score
function
dock
top
candid
molecul
obtain
best
score
shape
complementar
score
function
dock
compound
reestim
use
cscore
total
compound
cscore
best
score
cscore
subsequ
dock
rank
use
flexx
program
final
compound
select
accord
score
flexx
biolog
assay
enzymat
assay
timeconsum
therefor
surfac
plasmon
reson
spr
measur
use
primari
screen
determin
bind
affin
candid
molecul
cypa
immobil
cypa
result
reson
signal
reson
unit
ru
among
compound
biosensor
ru
compound
concentrationdepend
collect
data
indic
compound
bind
cypa
vitro
bind
affin
cyclophilin
submicroor
micromolar
rang
k
compound
could
design
binder
hit
cypa
chemic
structur
bind
affin
shown
figur
structur
hit
divid
three
class
class
includ
eight
compound
contain
sulfanilamid
moieti
compound
class
ii
compound
acylhydrazon
deriv
compound
class
iii
compris
compound
distinct
structur
charact
fig
consid
structur
similar
bind
affin
cypa
took
compound
class
compound
class
iii
leader
structur
optim
total
compound
design
synthes
chemic
structur
shown
tabl
compound
synthes
rout
outlin
scheme
detail
synthet
procedur
structur
character
describ
experiment
section
tabl
four
compound
ie
remark
inhibit
ppias
activ
cypa
percent
inhibit
lm
indic
four
compound
cypa
inhibitor
therefor
determin
ic
valu
respect
lm
fig
addit
bind
affin
analogu
determin
use
spr
technolog
result
also
list
tabl
ppias
activ
compound
consist
correl
spr
bind
affin
reason
may
protein
immobil
sensor
chip
spr
assay
affect
conform
flexibl
protein
accordingli
good
binder
identifi
spr
assay
may
good
inhibitor
find
cypa
inhibitor
rather
binder
effect
compound
ppias
activ
cypa
determin
test
immunosuppress
effect
antiprolifer
activ
spleen
cell
vitro
four
inhibitor
evalu
result
list
tabl
indic
compound
show
partial
influenc
viabil
spleen
cell
remark
effect
concentr
compound
lm
inhibit
prolifer
mous
spleen
cell
induc
con
slightli
lower
csa
indic
compound
good
lead
design
potent
immunosuppress
agent
valu
indic
mean
sd
three
experi
use
three
mice
triplic
set
assay
b
oneway
analysi
varianc
reveal
signific
effect
p
gain
structur
inform
structur
optim
bind
model
design
compound
cypa
gener
base
dock
simul
figur
show
interact
model
four
potent
inhibitor
cypa
figur
one
see
two
bind
site
surfac
bind
groov
cypa
site
small
bind
pocket
form
near
site
larger
pocket
call
site
b
form
two
site
bind
model
indic
class
compound
tabl
interact
cypa
similar
way
common
sulfanilamid
moieti
occupi
polar
bind
site
site
b
form
three
four
hydrogenbond
hbond
residu
fig
quinolin
ring
pyridin
ring
aryl
ring
fill
hydrophob
pocket
site
quinolin
moieti
pyridin
moieti
alkyl
group
act
linker
interact
saddl
part
site
b
interact
model
class
iii
compound
cypa
mostli
similar
class
compound
except
compound
extend
site
b
due
longer
linker
andor
substitu
summari
discov
four
potent
cypa
inhibitor
use
structurebas
virtual
screen
approach
conjunct
chemic
synthesi
bioassay
one
compound
activ
close
potenc
csa
inhibit
prolifer
spleen
cell
demonstr
compound
may
good
lead
discov
new
immunosuppress
agent
discov
small
molecul
cypa
inhibitor
urgent
need
new
chemic
structur
produc
studi
signific
reagent
chemic
purchas
lancast
acro
shanghai
chemic
reagent
compani
yield
optim
melt
point
measur
capillari
tube
sgw
melt
point
apparatu
without
correct
nuclear
magnet
reson
nmr
spectra
given
brucker
nmr
tm
chemic
shift
report
part
per
million
ppm
downfield
tetramethylsilan
proton
coupl
pattern
describ
singlet
doublet
triplet
quartet
q
multiplet
broad
br
lowand
highresolut
mass
spectra
lrm
hrm
given
electr
electrospray
matrixassist
laser
desorpt
ioniz
ei
esi
maldi
produc
finnigan
lcqdeca
spectromet
ionspec
mixtur
chlorid
g
mmol
compound
g
mmol
pyridin
ml
mixtur
compound
g
mmol
naoh
g
mmol
h
ml
reflux
h
gener
yellow
solut
acidifi
ph
cool
room
temperatur
precipit
collect
wash
h
dri
afford
compound
g
yellow
solid
mp
eim
mz
gener
procedur
prepar
describ
acid
illustr
scheme
isatin
mmol
mmol
koh
pellet
mmol
dissolv
etoh
ml
reaction
mixtur
stir
h
mixtur
condens
dilut
water
acidifi
concd
hcl
precipit
collect
figur
twodimension
represent
interact
mode
compound
b
c
cypa
drawn
use
ligplot
program
distanc
donor
acceptor
less
consid
hydrogenbond
distanc
two
hydrophob
atom
consid
hydrophob
interact
mixtur
g
mmol
maleic
acid
g
mmol
heat
melt
h
solid
obtain
cool
tritur
et
collect
suction
filtrat
filter
cake
recrystal
etoh
yield
benzen
sulfonamid
suspens
acid
g
mmol
redistil
socl
ml
reflux
gentli
h
clear
solut
result
socl
evapor
reduc
pressur
yellow
solid
thu
obtain
use
next
step
without
purif
mixtur
yellow
solid
thu
obtain
sulfisoxazol
g
mmol
pyridin
ml
benzenesulfonamid
n
n
n
n
benzenesulfonamid
compound
purifi
flash
chromatographi
etoacpetroleum
ether
vv
n
n
n
